Name: Latest research reports of Gland Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Gland Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Gland Pharma Ltd.

NSE: GLAND | BSE: 543245 | ISIN: INE068V01023 | Industry: Pharmaceuticals
| Mid-range Performer

1559.5000 24.40 (1.59%)

NSE Apr 03, 2025 15:31 PM

29.78% Fall from 52W High

Volume: 2.5M

High volume today

Gland Pharma Ltd.

24 Oct 2021

1559.50

1.59%

Robust show despite industry headwinds

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered in-line 2QFY22 results, led by a strong revenue growth across all geographies, despite increasing cost pressure on account of supply disruptions. With vaccine batch validation completed for Sputnik Lite and 2nd dose, GLAND awaits clarity on the lifting of export restrictions by the government. We lower our EPS estimate by 4%/2% for FY22/FY23, mainly to factor in some delay in commercialization of the Sputnik contract. We remain positive on GLAND based on its a) complex product filings including peptides, longacting injectables for regulated markets, b) commercialization of the Sputnik...

Gland Pharma Ltd. is trading at high day volume of 2.5M.